ADMA Biologics board member Bryant Fong resigns; committee chairs reassigned

ADMA BIOLOGICS, INC.

Bryant Fong resigned from board effective Nov 19, 2024 to focus on other roles; no disagreements.
Young T. Kwon appointed Chairman of Audit Committee and designated audit committee financial expert.
Steven A. Elms added to Audit Committee.
Alison C. Finger added to Governance and Nominations Committee and Compensation Committee.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bryant E. Fong

member of the Board of Directors

ADMA · ADMA BIOLOGICS, INC.

Effective: 2024-11-19
Filed: November 21, 2024, 6:59 PM ET

On November 19, 2024, Bryant E. Fong notified ADMA Biologics, Inc. (the “Company”) that he resigned, effective immediately, as a member of the Company’s Board of Directors (the “Board”) and any committees of the Board in order to devote more time to his roles as Managing Director of Biomark Capital Fund and as Partner and Co-Portfolio Manager of Stonepine Capital Management.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bryant E. Fong resigned as member of the Board of Directors at ADMA BIOLOGICS, INC..

Action: resigned
Role: member of the Board of Directors

Exact text from the filing

On November 19, 2024, Bryant E. Fong notified ADMA Biologics, Inc. (the “Company”) that he resigned, effective immediately, as a member of the Company’s Board of Directors (the “Board”) and any committees of the Board in order to devote more time to his roles as Managing Director of Biomark Capital Fund and as Partner and Co-Portfolio Manager of Stonepine Capital Management.

View on SEC.gov

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-047487

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.